Interestingly, a recently published review has discussed the therapeutic potential of targeting HSPs along with the PD-1/PD-L1 immune checkpoint axis in patients with myeloproliferative neoplasms without establishing the link or the interaction between these two targets [47]. This evidence concerns the gene CD274 and myeloproliferative disorder.